Corporation
AbbVie Corporation
- Meetings this Parliament
- 39
- With MPs
- 14
- Since Nov 2021
- 105
- Active registrations
- 1
Most recent reported meeting: Sep 23, 2026.
Lobbying by AbbVie Corporation: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Jul 2, 2026
Filed by Tanusree Misra, Vice-President and General Manager
Lobbyists
- Adam Cook · Manager, Market Access and Government Affairs, Ontario & Federal Programs
- Amelie McFadyen · Manager, Government Affairs and Policy
- Arima Ventin · Head, Market Access and Government Affairs
- Dana Corsen · Field Lead, Market Access & Government Affairs, Immunology
- David Link · Field Lead, Market Access & Government Affairs - Specialty
- Eric Pegolo · Manager, Market Access and Government Affairs, Ontario
- Harold Just · Manager, Market Access and Government Affairs - Oncology
- Herve Gaboury · Head, Market Access & HEOR, Oncology
- Jean-Luc Fortier · Manager, Market Access and Government Affairs, Quebec
- Jeff Onyskiw · Sr Manager, Market Access & Government Affairs – Saskatchewan, Manitoba, Federal Plans, Territories
- Judith Mergl · Director, Regulatory Affairs
- Lauren Fischer · Lead, Government Affairs & Policy
- Reema Malhotra · Field Lead, Market Access & Government Affairs - Oncology
- Sean Awalt · Manager, Market Access and Government Affairs, Atlantic
- Stephanie Sauvageau · Head, Medical Affairs
- Tanusree Misra · Vice-President and General Manager
Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration and Refugee Board (IRB), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, National Defence (DND), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (19)Hide details
- Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
- Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
- Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
- The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
- Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
- Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
- Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
- Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
- Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
- Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
- Communications with Health Canada regarding the application of its nitrosamine guidelines.
- Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
- Communications with Health Canada regarding guidelines for pediatric action plans.
- Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
- Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
- Communications regarding national pharmacare legislation, regulations, policies or programs.
- Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
- Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
- Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
Registration 965103-15270-50. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Tracey Ramsay (50), Rami Fayed (29), Tanusree Misra (17), Arima Ventin (9).
-
Reported by Arima Ventin · In-house (corporation)
- Maggie Chi · Member of Parliament, Parliamentary Secretary to the Minister of Health
- Justine Frame · Policy Advisor, Health Canada (HC)
- Nora Draper · Parliamentary Secretary Assistant, Health Canada (HC)
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices. Read more
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
-
Reported by Rami Fayed · In-house (corporation)
- Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Hosai Zurmati · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
-
Reported by Rami Fayed · In-house (corporation)
- Jean-Yves Duclos · Member of Parliament
- Steeve Lavoie · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Guillaume Bertrand · Director of Communications, Health Canada (HC)
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Rami Fayed · In-house (corporation)
- Karim Bardeesy · Parliamentary Secretary, Innovation, Science and Economic Development Canada (ISED)
- Chase Knight · Parliamentary Secretary Assistant and Parliamentary Affairs Advisor, Innovation, Science and Economic Development Canada (ISED)
Communication regarding free trade agreements as they relate to the biopharmaceutical industry. Read more
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
-
Reported by Rami Fayed · In-house (corporation)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
Communication regarding free trade agreements as they relate to the biopharmaceutical industry. Read more
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
-
Reported by Rami Fayed · In-house (corporation)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Hosai Zurmati · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
-
Reported by Rami Fayed · In-house (corporation)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Read more
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
-
Reported by Rami Fayed · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada. Read more
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Rami Fayed · In-house (corporation)
- Carlos Leitão · Parliamentary Secretary, Innovation, Science and Economic Development Canada (ISED)
- Cyril Nawar · Regional Advisor for Quebec, Innovation, Science and Economic Development Canada (ISED)
Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada. Read more
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Rami Fayed · In-house (corporation)
- Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada. Read more
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Rami Fayed · In-house (corporation)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
-
Reported by Rami Fayed · In-house (corporation)
- Helena Jaczek · Member of Parliament
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Read more
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
Communications regarding national pharmacare legislation, regulations, policies or programs.
-
Reported by Rami Fayed · In-house (corporation)
- Maggie Chi · Member of Parliament
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
-
Reported by Rami Fayed · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Read more
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
-
Reported by Rami Fayed · In-house (corporation)
- Stephanie Claxton · Director of Policy, Health Canada (HC)
- Roy Karam · Director of Operations, Health Canada (HC)
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more
Communications regarding national pharmacare legislation, regulations, policies or programs.
-
Reported by Rami Fayed · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Phillip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada. Read more
-
Reported by Rami Fayed · In-house (corporation)
- Judith Seidman · Senator, Senate of Canada
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance. Read more
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications regarding national pharmacare legislation, regulations, policies or programs.
-
Reported by Rami Fayed · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Read more
Communications regarding national pharmacare legislation, regulations, policies or programs.
-
Reported by Rami Fayed · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada. Read more
Communications regarding national pharmacare legislation, regulations, policies or programs.
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
-
Reported by Rami Fayed · In-house (corporation)
- Yves-François Blanchet · Member of Parliament
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Read more
-
Reported by Rami Fayed · In-house (corporation)
- Cory Olishansky · Consul and Trade Commissioner, Global Affairs Canada (GAC)
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada. Read more
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
-
Reported by Rami Fayed · In-house (corporation)
- Valerie Bradford · Member of Parliament, House of Commons
HealthIndustry
-
Reported by Rami Fayed · In-house (corporation)
- Madeleine Fequiere · Consul General of Canada in Chicago, Global Affairs Canada (GAC)
HealthIndustry
-
Reported by Rami Fayed · In-house (corporation)
- Scott Doidge · Director General, Indigenous Services Canada (ISC)
Health
-
Reported by Rami Fayed · In-house (corporation)
- Harold Dremin · Chief of Investor Services, Invest in Canada Hub
Economic DevelopmentResearch and Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.